share_log

Pfizer | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Pfizer Inc. (“Pfizer” or the “Reporting Person”)(22.6%)

Pfizer | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)

輝瑞 | SC 13D/A：超過5%持股股東披露文件(修正)
SEC announcement ·  03/22 21:07
牛牛AI助理已提取核心訊息
Pfizer Inc. has filed an amendment to its Schedule 13D with the U.S. Securities and Exchange Commission, disclosing its beneficial ownership of 2,062,236,079 Ordinary Shares of Haleon plc, which represents approximately 22.6% of Haleon's outstanding Ordinary Shares. This position includes both restricted American Depositary Shares and Ordinary Shares held by Pfizer's nominee. The filing, dated March 21, 2024, follows the completion of a secondary offering and a share buyback, where Haleon repurchased 102,272,727 Ordinary Shares from Pfizer at a price of £3.08 per share, amounting to approximately £315 million. The secondary offering and share buyback were both closed on March 21, 2024. Pfizer has also entered into a lock-up agreement restricting the sale of additional shares for 90 days post-offering. This amendment, Amendment No. 7, updates previous filings and provides the latest details on Pfizer's holdings and agreements with Haleon plc.
Pfizer Inc. has filed an amendment to its Schedule 13D with the U.S. Securities and Exchange Commission, disclosing its beneficial ownership of 2,062,236,079 Ordinary Shares of Haleon plc, which represents approximately 22.6% of Haleon's outstanding Ordinary Shares. This position includes both restricted American Depositary Shares and Ordinary Shares held by Pfizer's nominee. The filing, dated March 21, 2024, follows the completion of a secondary offering and a share buyback, where Haleon repurchased 102,272,727 Ordinary Shares from Pfizer at a price of £3.08 per share, amounting to approximately £315 million. The secondary offering and share buyback were both closed on March 21, 2024. Pfizer has also entered into a lock-up agreement restricting the sale of additional shares for 90 days post-offering. This amendment, Amendment No. 7, updates previous filings and provides the latest details on Pfizer's holdings and agreements with Haleon plc.
輝瑞公司已向美國證券交易委員會提交了附表13D的修正案，披露了其對Haleon plc2,06,236,079股普通股的實益所有權，約佔Haleon已發行普通股的22.6％。該頭寸包括限制性美國存托股份和輝瑞提名人持有的普通股。該文件日期爲2024年3月21日，是在二次發行和股票回購完成之後提交的，Haleon以每股3.08英鎊的價格從輝瑞回購了102,272,727股普通股，總額約爲3.15億英鎊。二次發行和股票回購均於2024年3月21日結束。輝瑞還簽訂了一項封鎖協議，限制在發行後的90天內出售額外股票。該修正案，即第7號修正案，更新了先前的文件，並提供了有關輝瑞持股和與Haleon plc協議的最新細節。
輝瑞公司已向美國證券交易委員會提交了附表13D的修正案，披露了其對Haleon plc2,06,236,079股普通股的實益所有權，約佔Haleon已發行普通股的22.6％。該頭寸包括限制性美國存托股份和輝瑞提名人持有的普通股。該文件日期爲2024年3月21日，是在二次發行和股票回購完成之後提交的，Haleon以每股3.08英鎊的價格從輝瑞回購了102,272,727股普通股，總額約爲3.15億英鎊。二次發行和股票回購均於2024年3月21日結束。輝瑞還簽訂了一項封鎖協議，限制在發行後的90天內出售額外股票。該修正案，即第7號修正案，更新了先前的文件，並提供了有關輝瑞持股和與Haleon plc協議的最新細節。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。